Pharmaceuticals News and Research

RSS

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, India (GPL), announced the opening of its new cGMP compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. T

4 Jun 2014

Propak Asia 2014 to be held at BITEC on June 11-14

ProPak Asia is Asia's No. 1 international food, drink and pharmaceutical processing, filling and packaging technology event, to take place for its successful 22nd edition on 11 to 14 June at Bangkok International Trade and Exhibition Centre (BITEC).

4 Jun 2014

arGEN-X, Shire Pharmaceuticals announce long-term strategic alliance in therapeutic antibodies

arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a long-term strategic alliance with Shire Pharmaceuticals.

4 Jun 2014

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

Provectus Biopharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that data on its investigational agent PV-10 for intralesional (IL) treatment of solid tumors were featured in two presentations in the Poster Highlights Session, Melanoma/Skin Cancers, on June 2, 2014 during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL.

4 Jun 2014

NeuroVive extends collaboration with Hospices Civils de Lyon

NeuroVive is extending its collaboration with Hospices Civils de Lyon (HCL) and Professor Ovize, which broadens the scope of NeuroVive's cardiovascular business area and creates the right conditions for the company to retain its leading position in mitochondrial medicine.

4 Jun 2014

Medicare to pay for hep C screenings for baby boomers

The decision comes amid controversy surrounding the costs of new drugs to treat the blood-borne virus. Meanwhile, two studies find that Medicare could save billions if doctors switched from an expensive eye medication to a similar, much cheaper one and, also, if Part D plans were selected based on the actual drugs patients take.

4 Jun 2014

Notre Dame professor receives GCE grant for global health and development research project

Marya Lieberman, associate professor of chemistry and biochemistry at the University of Notre Dame, has received a Grand Challenges Explorations grant, an initiative funded by the Bill & Melinda Gates Foundation. Lieberman will pursue an innovative global health and development research project, titled "Printed test cards for rapid field screening of human and animal medications."

4 Jun 2014

Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has been awarded funding of £2.2 million towards a Phase IIa clinical trial in tinnitus patients with its lead compound AUT00063, by the UK’s innovation agency, the Technology Strategy Board.

4 Jun 2014

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Polyarticular Juvenile Idiopathic Arthritis (PJIA) is a type of Juvenile Idiopathic Arthritis (JIA), a group of Rheumatoid Arthritis (RA) diseases that manifests in multiple ways in children.

3 Jun 2014

Syngene International, Bristol-Myers Squibb extend drug discovery and development collaboration

Bristol-Myers Squibb and Syngene International, India's largest contract research organization, today announced a five-year extension of their drug discovery and development collaboration in India.

3 Jun 2014

UK makes £5.64M investment in most advanced crystallography technology

The UK's structural biology community will have access to the most advanced crystallography technology in the world thanks to a - £5.64M investment from UK research funders.

3 Jun 2014

Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Teva Pharmaceutical Industries Ltd., and Labrys Biologics, Inc., a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, today announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva's array of biotechnology assets and capabilities.

3 Jun 2014

Vanda’s HETLIOZ MAA for Non-24-Hour Sleep-Wake Disorder accepted for evaluation by the EMA

Vanda Pharmaceuticals Inc. announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

3 Jun 2014

Jazz Pharmaceuticals' JZP-110 improves symptoms of EDS in adults with narcolepsy

Jazz Pharmaceuticals plc today presented data from the Phase 2b study evaluating JZP-110 (formerly known as ADX-N05) as a potential new treatment for the symptoms of excessive daytime sleepiness (EDS) in adults with narcolepsy.

3 Jun 2014

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

We already understand the many steps involved in blood clotting in great mechanistic detail. The process of blood vessels closing off in response to injury is necessary for preserving life, but blood platelets that are over-active, or activated inappropriately because of unstable plaque, can lead to heart attacks and strokes.

3 Jun 2014

Cerenis’ SAMBA and MODE Phase II Studies Meet Primary Endpoints for Treatment of FPHA, HoFH

Cerenis Therapeutics, the biopharmaceutical company, today announced that two of its Phase II studies, SAMBA and MODE (Modifying Orphan Disease Evaluation), with CER-001, an engineered human apoA-I-containing pre-β HDL mimetic, met their primary clinical endpoints in patients with Familial Primary Hypoalphalipoproteinemia (FPHA) and Homozygous Familial Hypercholesterolemia (HoFH), respectively.

2 Jun 2014

AMRI agrees to acquire OsoBio for $110 million

AMRI today announced that it has signed a definitive agreement to acquire all of the outstanding membership interests of Oso Biopharmaceuticals Manufacturing, LLC for $110 million in cash.

2 Jun 2014

Endo International subsidiary sells pharmaceutical drug discovery platform to AsanaBioSciences

Endo International plc today announced that its Endo Pharmaceuticals subsidiary has completed the sale of its branded pharmaceutical drug discovery platform to AsanaBioSciences, LLC, an independent member of the Amneal Alliance of Companies.

2 Jun 2014

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

ARIAD Pharmaceuticals, Inc. today announced, for the first time, data from its Phase 2 trial of Iclusig (ponatinib) in adult patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

2 Jun 2014

Validic adds several new clients to expand global digital health marketplace

Validic, the healthcare industry's premier technology platform for accessing digital health data, announced today the addition of several new clients and integration partners, as they continue to expand and grow their global digital health marketplace.

2 Jun 2014

Pharmaceuticals News and Research

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Propak Asia 2014 to be held at BITEC on June 11-14

arGEN-X, Shire Pharmaceuticals announce long-term strategic alliance in therapeutic antibodies

Provectus’ PV-10 data for intralesional treatment of solid tumors presented at ASCO annual meeting

NeuroVive extends collaboration with Hospices Civils de Lyon

Medicare to pay for hep C screenings for baby boomers

Notre Dame professor receives GCE grant for global health and development research project

Autifony Therapeutics awarded £2.2 million to progress first-in-class drug for tinnitus into Phase IIa study

Polyarticular juvenile idiopathic arthritis (PJIA): an interview with Dr. Kramer, VP, Immunology and Infectious Diseases Medical Unit, Genentech

Syngene International, Bristol-Myers Squibb extend drug discovery and development collaboration

UK makes £5.64M investment in most advanced crystallography technology

Teva Pharmaceutical Industries enters into definitive agreement to acquire Labrys

Vanda’s HETLIOZ MAA for Non-24-Hour Sleep-Wake Disorder accepted for evaluation by the EMA

Jazz Pharmaceuticals' JZP-110 improves symptoms of EDS in adults with narcolepsy

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

Cerenis’ SAMBA and MODE Phase II Studies Meet Primary Endpoints for Treatment of FPHA, HoFH

AMRI agrees to acquire OsoBio for $110 million

Endo International subsidiary sells pharmaceutical drug discovery platform to AsanaBioSciences

ARIAD reports data from Iclusig Phase 2 trial in adult patients with gastrointestinal stromal tumors

Validic adds several new clients to expand global digital health marketplace

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence